Ampersand Biomedicines

Ampersand Biomedicines is a Boston-based biotechnology company founded in 2020 out of Flagship Pioneering that designs programmable biologic medicines intended to act only at the site of disease. Its computationally powered Address, Navigate, Determine (AND) Platform pairs a multi-omics "Address Map" of healthy and diseased human tissue with high-throughput microfluidic binder generation and AI-guided binder prediction to design AND-Body therapeutics, which combine a localizing element with an actuator so activity is conditional on the target tissue. The company raised a $65M Series B in March 2025 from Flagship Pioneering and Eli Lilly, and partners with Pioneering Medicines and Pfizer. It is a preclinical therapeutics developer, not a software vendor: the computational platform is internal tooling for its own drug discovery and is not offered to third parties, and the company publishes no public API, developer portal, SDK, or machine-readable specification.

Ampersand Biomedicines is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Drug Discovery, and Life Sciences.

Ampersand Biomedicines’ developer surface includes engineering blog and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyTherapeuticsDrug DiscoveryLife SciencesComputational BiologyPrecision MedicineFlagship Pioneering

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 8.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ampersand-biomedicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

Website

Blog

Blog

Careers

Careers

LinkedIn

Twitter

Twitter

Investor

Investor

Other 2

Properties that don't map to a standard resource type

CookiePolicy

CookiePolicy

Profile

Profile

Source (apis.yml)

aid: ampersand-biomedicines
name: Ampersand Biomedicines
description: 'Ampersand Biomedicines is a Boston-based biotechnology company founded in 2020 out of Flagship Pioneering that
  designs programmable biologic medicines intended to act only at the site of disease. Its computationally powered Address,
  Navigate, Determine (AND) Platform pairs a multi-omics "Address Map" of healthy and diseased human tissue with high-throughput
  microfluidic binder generation and AI-guided binder prediction to design AND-Body therapeutics, which combine a localizing
  element with an actuator so activity is conditional on the target tissue. The company raised a $65M Series B in March 2025
  from Flagship Pioneering and Eli Lilly, and partners with Pioneering Medicines and Pfizer. It is a preclinical therapeutics
  developer, not a software vendor: the computational platform is internal tooling for its own drug discovery and is not offered
  to third parties, and the company publishes no public API, developer portal, SDK, or machine-readable specification.'
image: https://cdn.prod.website-files.com/62e1567a532ab570f765e32c/63beca5200a95d31d65346ad_Ampersand-logo-color.svg
url: https://raw.githubusercontent.com/api-evangelist/ampersand-biomedicines/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Ampersand Biomedicines is a preclinical therapeutics developer whose AND Platform is internal drug-discovery tooling,
    not a product — the corporate site at ampersand.bio has only Science, Pipeline, Team, News, Careers and Contact sections,
    no api/docs/developer subdomain resolves in DNS, and every contract-discovery path returned 404.
  evidence:
  - url: https://www.ampersand.bio/
    status: 200
  - url: https://www.ampersand.bio/openapi.json
    status: 404
  - url: https://www.ampersand.bio/llms.txt
    status: 404
  - url: https://www.ampersand.bio/.well-known/agent-card.json
    status: 404
  - url: https://www.ampersand.bio/.well-known/security.txt
    status: 404
  checked: '2026-08-06'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Therapeutics
- Drug Discovery
- Life Sciences
- Computational Biology
- Precision Medicine
- Flagship Pioneering
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ampersand-biomedicines-domain-security.yml
- type: Website
  url: https://www.ampersand.bio/
- type: Blog
  url: https://www.ampersand.bio/news
- type: Contact
  url: https://www.ampersand.bio/contact
- type: PrivacyPolicy
  url: https://www.ampersand.bio/privacy-policy
- type: CookiePolicy
  url: https://www.ampersand.bio/cookie-policy
- type: Careers
  url: https://www.ampersand.bio/careers
- type: LinkedIn
  url: https://www.linkedin.com/company/ampersand-biomedicines
- type: Twitter
  url: https://twitter.com/AmpersandBio
- type: Investor
  url: https://www.flagshippioneering.com/companies/ampersand-biomedicines
- type: Profile
  url: https://forgeglobal.com/ampersand-biomedicines_stock/